Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 3Prostatic Neoplasms 3Urinary Bladder Neoplasms 2Sarcoma 2Pancreatic Neoplasms 2Breast Neoplasms 2Urologic Neoplasms 1Urologic Diseases 1Urogenital Neoplasms 1Urogenital Diseases 1Urinary Bladder Diseases 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Ewing 1Prostate Adenocarcinoma 1Neoplasms by Site 1Neoplasms 1Neoplasm Metastasis 1Male Urogenital Diseases 1Lymphedema 1Lung Neoplasms 1Gallbladder Neoplasms 1Financial Stress 1Female Urogenital Diseases 1Endometrial Neoplasms 1Encopresis 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1

Interventions

Gemcitabine 8Cisplatin 8pembrolizumab 4durvalumab 4Specimen Handling 3Platinum 3Oxaliplatin 3Leucovorin 31,2-diaminocyclohexaneplatinum II citrate 3Taxes 2Nivolumab 2Magnetic Resonance Spectroscopy 2Folfox protocol 2Fluorouracil 2Biopsy 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2zanidatamab 1trastuzumab deruxtecan 1tivozanib 1peposertib 1guadecitabine 1fludarabine 1dehydroftorafur 1binimetinib 1avelumab 1atezolizumab 1Trastuzumab 1Radiation Dose Hypofractionation 1Radiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gallbladder Neoplasms × Radiation Dose Hypofractionation × 90 days × Clear all
NCT04068194 2026-05-13

Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
103 enrolled
Gastrointestinal

Gallbladder Neoplasms, Neoplasm Metastasis, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡